Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
Get Alerts OTIC Hot Sheet
Join SI Premium – FREE
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overview at the Raymond James 2020 Human Health Innovation Conference (Virtual) on Thursday June 18, 2020 at 2:20 p.m. ET (11:20 a.m. PT).
A live audio webcast of the presentations will be available through the Events page of the company's website (www.otonomy.com).
About Otonomy Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne RamseyVice President404.865.3601 [email protected]
Investor Inquiries:Westwicke ICRRobert H. UhlManaging Director858.356.5932[email protected]
Source: Otonomy, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Availability of the Annual Financial Report of Societe Generale SCF
- Gray Television Partners with Revamped Arena Football League to Bring Local Spring Football to Viewers Free Over-The-Air Starting April 27
- Cumulus Media’s Westwood One Presents Exclusive Live Audio Coverage of the 2024 NCAA® Women’s Basketball Championship
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!